{
}
Coloplast A/S has faced a decline in its share price, recently falling to EUR 112.38, reflecting a 4.66% loss over the month. The company, which specializes in medical products for urology and wound care, announced the sale of its skin care division to refocus on core competencies. Despite recent challenges, the share has shown an annual increase of 8.10%.
UBS has upgraded Coloplast A/S to a "neutral" rating from "sell," citing improved market dynamics and reduced risks associated with the company's operations. The revision reflects a reassessment of competitive pressures and growth investments, particularly in wound biologics and continence care. Analysts project an 8% compound annual revenue growth rate and an 11% increase in earnings per share from 2024 to 2028, with the stock trading at a 40% sector premium.
UBS has upgraded Coloplast A/S to a "neutral" rating from "sell," citing improved market dynamics and a reassessment of risks. The firm noted reduced competitive pressures and a more conservative market outlook, with expectations of steady growth, projecting an 8% annual revenue increase and an 11% rise in earnings per share from 2024 to 2028. The stock is now trading at a 40% sector premium, aligning with historical averages, and UBS set a price target of DKK 858, reflecting a valuation of 33 times estimated 2025 earnings.
UBS has upgraded Coloplast A/S to a neutral rating. The company specializes in disposable medical products, with net sales divided into hygiene products (43.4%), ostomy care (36.8%), wound and skin care (11.9%), and voice and respiratory care (7.9%). Geographically, sales are primarily from the United States (21%), the United Kingdom (14%), and other regions (52.8%).
UBS has upgraded Coloplast A/S to a neutral rating. The company specializes in disposable medical products, with net sales primarily from hygiene products (43.4%), ostomy care (36.8%), wound care (11.9%), and voice/respiratory care (7.9%). Geographically, sales are led by the U.S. (21%), the U.K. (14%), and France (10.8%).
UBS has upgraded Coloplast to a neutral rating while maintaining its price target at DKK 858, citing reduced risks following the recent sale of its skin care business, which led to a 1% cut in sales estimates. The company specializes in disposable medical products, with significant sales in the USA and UK.
UBS has upgraded Coloplast A/S to a neutral rating. The company specializes in disposable medical products, with net sales primarily from hygiene products (43.4%), ostomy care (36.8%), wound care (11.9%), and voice/respiratory care (7.9%). Geographically, sales are led by the U.S. (21%), the U.K. (14%), and France (10.8%).
UBS has upgraded Coloplast A/S to a neutral rating. The company specializes in disposable medical products, with net sales primarily from hygiene products (43.4%), ostomy care (36.8%), wound and skin care (11.9%), and voice and respiratory care (7.9%). Geographically, sales are led by the United States (21%), the United Kingdom (14%), and France (10.8%), with other regions accounting for 52.8%.
UBS has upgraded Coloplast to a neutral rating while maintaining a price target of DKK 858. Coloplast A/S focuses on disposable medical products, with sales divided into hygiene products (43.4%), ostomy care (36.8%), wound and skin care (11.9%), and vocal and respiratory care (7.9%). Geographically, the company generates 1.4% of sales in Denmark, 21% in the USA, 14% in the UK, 10.8% in France, and 52.8% from other regions.
UBS has upgraded Coloplast to a neutral rating while maintaining a price target of DKK 858. The company specializes in disposable medical products, with net sales primarily from hygiene products (43.4%), ostomy care (36.8%), wound and skin care (11.9%), and voice and respiratory care (7.9%). Geographically, sales are distributed with 21% in the U.S., 14% in the U.K., and 10.8% in France, among others.
Coloplast A/S
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Coloplast Faces Stock Decline Amid Strategic Shift and Market Challenges
01:12 12.12.2024
UBS Upgrades Coloplast to Neutral Amid Improved Market Dynamics and Growth Prospects
15:00 11.12.2024
ubs upgrades coloplast to neutral amid improved market dynamics and growth prospects
15:00 11.12.2024
UBS Upgrades Coloplast to Neutral Amid Diverse Medical Product Offerings
10:53 11.12.2024
UBS Upgrades Coloplast to Neutral Amid Diverse Medical Product Portfolio
10:38 11.12.2024
UBS Upgrades Coloplast to Neutral Following Skin Care Business Sale
10:38 11.12.2024
ubs upgrades coloplast to neutral amid diverse medical product offerings
10:38 11.12.2024
UBS Upgrades Coloplast to Neutral Amid Diverse Medical Product Portfolio
10:38 11.12.2024
UBS Upgrades Coloplast to Neutral with Price Target of DKK 858
09:55 11.12.2024
UBS Upgrades Coloplast to Neutral with Price Target of DKK 858
09:55 11.12.2024
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Finance Mergers & Acquisitions
Hedge Funds & Private Equity
Global Trade Developments
Global Financial Events
Financial Scams and Security
Market Analysis and Predictions
Government Policies
Banking Regulations
CEO Changes
Economic Sanctions
Startups & Entrepreneurship
Industry Mergers & Acquisitions
Retail and Consumer Goods
Central Bank Actions
Workplace Trends
International Relations
Government Economic Policies
Countries:
Companies:
JPMorgan Chase & Co.
Tesla, Inc.
The Goldman Sachs Group, Inc.
Wells Fargo & Company
Bank of America Corporation
Barclays PLC
Apple Inc.
Citigroup Inc.
Morgan Stanley
Berkshire Hathaway Inc.
Microsoft Corporation
SpaceXCoin USD
The Charles Schwab Corporation
AMERICAN EXPRESS
Amazon.com, Inc.
U.S. Bancorp
UBS Group AG
Banco Santander, S.A.
Deutsche Bank Money Market PP
Citizens, Inc.
Currencies:
United States Dollar
Euro
Indian Rupee
Chinese Yuan
Japanese Yen
British Pound Sterling
South Korean Won
Swiss Franc
United Arab Emirates Dirham
Canadian Dollar
Israeli New Shekel
Swedish Krona
Mexican Peso
New Taiwan Dollar
Egyptian Pound
People: